Harel Insurance Investments & Financial Services Ltd. Has $1.38 Billion Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,956,714 shares of the company’s stock after purchasing an additional 1,004,941 shares during the period. Teva Pharmaceutical Industries accounts for about 9.4% of Harel Insurance Investments & Financial Services Ltd.’s portfolio, making the stock its biggest position. Harel Insurance Investments & Financial Services Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,384,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Allworth Financial LP lifted its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the period. Grove Bank & Trust lifted its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 465,931 shares of company stock valued at $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $31.80 on Wednesday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm has a market capitalization of $36.56 billion, a price-to-earnings ratio of 23.91, a PEG ratio of 3.42 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock’s 50-day simple moving average is $34.00 and its 200-day simple moving average is $32.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TEVA shares. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.